-
Apnimed raises funding to advance sleep apnea therapeutic
pharmaceutical-technology
March 29, 2021
Apnimed has raised $25m in a Series B financing round to advance its oral disease-modifying therapeutic AD109 for obstructive sleep apnea (OSA) and support its ongoing development and commercialisation plans.
-
Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea
pharmaceutical-business-review
November 27, 2020
Apnimed announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.
-
Reduction in Tongue Fat Can Improve Obstructive Sleep Apnea
drugs
January 15, 2020
For individuals with obesity and obstructive sleep apnea (OSA), a reduction in tongue fat associated with weight loss correlates with improvement in the apnea-hypopnea index (AHI), according to a study published online January in the American Journal of R
-
Obstructive Sleep Apnea May Be Underdiagnosed in Women
drugs
December 27, 2019
Men and women experience obstructive sleep apnea (OSA) during REM sleep at similar rates, according to a study published online in SLEEP.
-
CPAP Mask Helps Patients With Mild Obstructive Sleep Apnea
drugs
December 12, 2019
Among patients with mild obstructive sleep apnea (OSA), quality of life is improved at three months for those receiving continuous positive airway pressure (CPAP) therapy ...
-
Prevalence of Apnea High in Individuals With Resistant HTN
drugs
September 16, 2019
Individuals with resistant hypertension (RH) have a high prevalence of obstructive sleep apnea (OSA), with a dose-response association observed between the severity of OSA and blood pressure (BP) values...
-
Sleep Apnea Traits May Predict Response to Oral Appliance Tx
drugs
August 12, 2019
Quantifying obstructive sleep apnea (OSA) traits using clinical polysomnography may identify an endotype-based subgroup of patients that is responsive to oral appliance therapy...